Search Results

You are looking at 121 - 130 of 391 items for :

  • Refine by Access: All x
Clear All
Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

% and a PFS of 4.3 months in the chemotherapy-alone arm. Grade 3 AEs in the ramucirumab arm included thrombocytopenia (15%), neutropenia (13%), fatigue (12%), and nausea (10%). Table 2 Ongoing Phase II and Phase III Trials in the United States of

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

.2% (3 stringent CRs, 10 VGPRs, 18 PRs). Median response duration was 7.4 months and median time to progression was 3.7 months; the estimated 1-year OS rate was 65%. 22 Adverse events reported included fatigue (39.6%), anemia (33.0%), nausea (29.2%), and

Full access

Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

particularly at risk for experiencing high symptom burden and loss of muscle. 16 – 18 Patients with muscle loss often require hospital-level care to address treatment adverse effects and high symptom burden (eg, pain, fatigue, nausea). 19 Notably

Full access

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

%), anemia (13% vs 0%), and nausea (20% vs 2%). Crossover was allowed for the cetuximab/irinotecan group, and 48% of those patients received vemurafenib at time of progression. Of those who crossed over, the partial response rate was 17% and the stable

Full access

Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer

Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

therapy. 5 , 6 , 9 Gastrointestinal irAEs frequently involve the colon, liver, and stomach and present with nausea, vomiting, diarrhea, rectal bleeding, or abdominal pain. 9 – 14 Rare gastrointestinal irAEs have been reported, such as esophagitis

Full access

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

(range, 1.9 to ≥21.8 months). The most common adverse effects with pembrolizumab were fatigue, pruritus, diarrhea, anorexia, constipation, nausea, rash, fever, cough, dyspnea, and musculoskeletal pain. Pembrolizumab also may be associated with immune

Full access

Head and Neck Cancers, Version 2.2013

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, David E. Schuller, Jatin P. Shah, Sharon Spencer, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

; chemotherapy is often associated with oral mucositis, nausea, and vomiting. 1 NCCN Guidelines Insights : Head and Neck Cancers, Version 2.2013 Version 2.2013 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines

Full access

Are New Oral Anticoagulants Ready for Use in Patients With Cancer?

Paul C. Hendrie and David A. Garcia

alternative to the parenteral heparins. This is desirable for most patients with cancer, but may not be useful in patients whose gastrointestinal tract is unavailable because of disease involvement, surgery, radiation, or nausea. These agents also have easy

Full access

Diagnostic and Treatment Considerations When Newly Diagnosed Breast Cancer Coincides With Pregnancy: A Case Report and Review of Literature

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

maternal grandmother, who was diagnosed and treated at 55 years of age. Review of systems was positive for intermittent headaches consistent with previous self-limiting migraines and occasional nausea without emesis, which had been diminishing in frequency

Full access

Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?

Joseph M. Herman and Albert C. Koong

. Nonetheless, these multiagent regimens can cause more toxicity than single-agent chemotherapy, including nausea, vomiting, infection, and severe neuropathy. These toxicities can be debilitating, particularly with chronic administration. Efforts to include